Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer20201110133855
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
November 10, 20200 comments
WINTER PARK, Fla., Nov. 10, 2020 /PRNewswire/ -- Cytocom, Inc. (Cytocom), a leading biopharmaceutical company in the area of immune-modulation, today ...
Cytocom Strategic Vision Conference Call Reminder20201027174551
Cytocom Strategic Vision Conference Call Reminder
October 27, 20200 comments
WINTER PARK, Fla., Oct. 27, 2020 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company in the area of immune-modulation, today announced ...
Cytocom, Inc. Issues Shareholder Letter20201021123436
Cytocom, Inc. Issues Shareholder Letter
October 21, 20200 comments
WINTER PARK, Fla., Oct. 21, 2020 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company in the area of immune-modulation, today announced ...
Cytocom and Cleveland BioLabs Announce Definitive Merger Agreement20201020003614
Cytocom and Cleveland BioLabs Announce Definitive Merger Agreement
October 20, 20200 comments
WINTER PARK, Fla., and BUFFALO, NY, October 20, 2020 /PRNewswire/ -- Cytocom, Inc. (Cytocom), a leading biopharmaceutical company in the area of immun...
Cytocom, Inc. Announces Agreement to Reacquire Rights to Lead Drug Candidate CYTO-201 and CYTO-401 in Emerging Markets20200820213847
Cytocom, Inc. Announces Agreement to Reacquire Rights to Lead Drug Candidate CYTO-201 and CYTO-401 in Emerging Markets
August 20, 20200 comments
WINTER PARK, Fla., Aug. 20, 2020 /PRNewswire/ -- Cytocom, Inc. (Cytocom), a clinical-stage biopharmaceutical company developing novel immune modulatin...
Cytocom Announces Acquisition of ImQuest Life Sciences20200720121029
Cytocom Announces Acquisition of ImQuest Life Sciences
July 20, 20200 comments
WINTER PARK, Fla., July 20, 2020 /PRNewswire/ -- Cytocom, Inc., a private clinical-stage biopharmaceutical company developing novel immune modulating ...
Cytocom, Inc. Announces Successful Completion of Type-B Pre-IND Meeting with FDA Regarding Proposed Phase 2 Clinical Trial of CYTO-201 in COVID-19 Patients20200629114922
Cytocom, Inc. Announces Successful Completion of Type-B Pre-IND Meeting with FDA Regarding Proposed Phase 2 Clinical Trial of CYTO-201 in COVID-19 Patients
June 29, 20200 comments
WINTER PARK, Fla., June 29, 2020 /PRNewswire/ -- Cytocom, Inc. (Cytocom), a private clinical-stage biopharmaceutical company developing novel immune m...
Immune Therapeutics Announces that Equity Partner, Cytocom, Inc., has Filed an Investigational New Drug Application to Conduct a Phase II Clinical Trial Evaluating CYTO-201 Treatment in COVID-19 Patients20200609134518
Immune Therapeutics Announces that Equity Partner, Cytocom, Inc., has Filed an Investigational New Drug Application to Conduct a Phase II Clinical Trial Evaluating CYTO-201 Treatment in COVID-19 Patients
June 9, 20200 comments
Winter Park, Florida–(Newsfile Corp. – June 9, 2020) – Immune Therapeutics, Inc. (OTC Pink: IMUN), announced today that equity partner, Cytocom, Inc.,...
Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-1920200410122646
Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19
April 10, 20200 comments
Immune Therapeutics, Inc. Signs Binding Letter of Intent to Collaborate with Cytocom, Inc. to Develop Lodonal™ and Other Drugs for COVID-19; Other Dru...